专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP4182453A1 PEPTIDES FOR THE TREATMENT OF CANCER 审中-实审
公开(公告)号：EP4182453A1
公开(公告)日：2023-05-24
申请号：EP21765843.4
申请日：2021-08-11
申请人： Klinikum rechts der Isar der Technischen Universität München
发明人： KONG, Bo
IPC分类号： C12N9/12 , A61K38/00 , A61K45/00 , A61P35/00

4. 发明公开

EP3421037A1 RLS TREATMENT WITH INHIBITORS OF THE CEREBLON (CRBN) PROTEIN 审中-公开
公开(公告)号：EP3421037A1
公开(公告)日：2019-01-02
申请号：EP17178451.5
申请日：2017-06-28
申请人： Klinikum rechts der Isar der Technischen Universität München
发明人： WINKELMANN, Juliane
IPC分类号： A61K31/454 , A61K31/7105 , A61K31/713 , A61P25/00 , G01N33/68
摘要： The present invention relates to an inhibitor of the cereblon (CRBN) protein for use in the prevention and/or treatment of restless leg syndrome (RLS) and/or diseases associated therewith. The invention also relates to a method of preventing and/or treating restless leg syndrome (RLS) and/or diseases associated therewith comprising administering a pharmaceutically effective amount of an inhibitor of the cereblon (CRBN) protein to a subject in need thereof. Finally, the invention also relates to a method of identifying an inhibitor of the cereblon (CRBN) protein suitable as a lead compound and/or as a medicament for the prevention and/or treatment of restless leg syndrome (RLS) and/or diseases associated therewith.

5. 发明公开

EP3246413A1 A METHOD FOR PREDICTING A BREAST CANCER PATIENT'S RESPONSE TO ANTHRACYCLINE TREATMENT 审中-公开
标题翻译：一种预测乳腺癌患者对蒽环类治疗反应的方法
公开(公告)号：EP3246413A1
公开(公告)日：2017-11-22
申请号：EP16170625.4
申请日：2016-05-20
申请人： Klinikum rechts der Isar der Technischen Universität München , Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH
发明人： SCHMITT, Manfred , NAPIERALSKI, Rudolf , SCHÜREN, Elisabeth , AUBELE, Michaela , ABSMAIER, Magdalena , GROSS, Eva , SCHUSTER, Tibor , HÖFLER, Heinz , KIECHLE, Marion
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/154
摘要： The present invention relates to a method for predicting a breast cancer patient's response to anthracycline treatment.
摘要翻译：本发明涉及用于预测乳腺癌患者对蒽环类抗生素治疗的反应的方法。

6. 发明公开

EP3197497A1 METHOD FOR ASSESSING THE EFFICACY OF IMIDS AND COMPOSITION OR COMBINATION FOR USE IN TREATING IMID SENSITIVE DISEASES 审中-公开
标题翻译：评估IMIDS和组合物或用于治疗IMID敏感疾病的组合的效果的方法
公开(公告)号：EP3197497A1
公开(公告)日：2017-08-02
申请号：EP15766854.2
申请日：2015-09-23
申请人： Klinikum rechts der Isar der Technischen Universität München
发明人： BASSERMANN, Florian , EICHNER, Ruth , FERNANDEZ-SAIZ, Vanessa
IPC分类号： A61K45/06 , A61P35/00 , A61K31/4545 , G01N33/00
CPC分类号： A61K31/454 , A61K31/713 , A61K45/06 , C12N15/1138 , C12N2310/14 , C12N2310/531 , C12N2320/31 , G01N33/57492 , G01N33/6872 , G01N2333/705 , G01N2333/70503 , G01N2800/52 , A61K2300/00
摘要： The invention relates to a combination of an immunomodulatory imide drug (IMID) and an inhibitor of CD147 and/or an inhibitor of MCT1 for use in treating a disease in a subject. It further relates to an inhibitor of CD147 and/or an inhibitor of MCT1 for use in treating a disease in a patient, wherein the patient is IMID resistant. It further relates to a method of monitoring the efficacy of an IMiD treatment regimen by comparing the protein level of CD147 and/or MCT1 in samples obtained from a subject prior and during IMiD treatment.
摘要翻译：本发明涉及免疫调节性酰亚胺药物（IMID）与CD147抑制剂和/或MCT1抑制剂的组合，用于治疗受试者的疾病。本发明还涉及用于治疗患者疾病的CD147抑制剂和/或MCT1抑制剂，其中患者对IMID有抵抗力。本发明还涉及通过比较在IMiD治疗之前和期间从受试者获得的样品中的CD147和/或MCT1的蛋白质水平来监测IMiD治疗方案的功效的方法。

7. 发明公开

EP3097892A1 CANNULA AND INSTRUMENT FOR INSERTING A CATHETER 审中-公开
标题翻译： KANÜLEUND INSTRUMENT ZUMEINFÜHRENEINES KATHETERS
公开(公告)号：EP3097892A1
公开(公告)日：2016-11-30
申请号：EP15169828.9
申请日：2015-05-29
申请人： Klinikum rechts der Isar der Technischen Universität München
发明人： Nasseri, Mohammad Ali , Maier, Mathias , Lohmann, Chris Patrick
IPC分类号： A61F9/00 , A61F9/007
CPC分类号： A61B17/3415 , A61B2017/0023 , A61B2090/306 , A61F9/0008 , A61F9/007 , A61F9/00736 , A61M25/0662 , A61M2025/0042
摘要： A cannula for inserting a catheter is provided. The cannula comprises a first channel (30) for receiving and guiding a catheter tube (26). The first channel (30) extends to a first opening (22) and has an end portion defining an insertion direction (I), such that a catheter tube (26) when being advanced and guided through the end portion of the first channel (30) exits the cannula through the first opening (22) in the insertion direction (I). The cannula further comprises a second channel (32) for receiving a pointing device for providing a pointing beam. The second channel (32) extends to a second opening (24) and has an end portion (34) defining a pointing direction (P). The pointing direction (P) points from the second opening (24) towards a location, which is located outside the cannula along the insertion direction (I) in front of the first opening (22).
摘要翻译：提供用于插入导管的套管。套管包括用于接收和引导导管（26）的第一通道（30）。第一通道（30）延伸到第一开口（22）并且具有限定插入方向（I）的端部，使得导管管（26）在被推进并被引导通过第一通道（30）的端部时）沿插入方向（I）通过第一开口（22）离开套管。套管还包括用于接收用于提供指向光束的指示装置的第二通道（32）。第二通道（32）延伸到第二开口（24）并且具有限定指向方向（P）的端部（34）。所述指示方向（P）从所述第二开口（24）朝着位于所述插管外侧的位置处沿着所述插入方向（I）位于所述第一开口（22）的前方。

8. 发明公开

EP3015855A1 Metal biosensors based on compounds with metal-sensitive chemical shifts for magnetic resonance spectroscopy and imaging 审中-公开
标题翻译：根据化合物与用于磁共振波谱和磁共振成像金属敏感性的化学位移金属生物传感器
公开(公告)号：EP3015855A1
公开(公告)日：2016-05-04
申请号：EP14190482.1
申请日：2014-10-27
申请人： Klinikum rechts der Isar der Technischen Universität München , Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH
发明人： Westmeyer, Gil Gregor , Mishra, Anurag , Pariani, Giorgio
IPC分类号： G01N24/08 , A61B5/055 , A61K49/06 , G01R33/28 , G01R33/465 , G01R33/56
CPC分类号： G01N24/08 , A61B5/055 , A61K49/103 , G01R33/281 , G01R33/465 , G01R33/5601
摘要： The present invention relates to the use of compounds with at least one metal-sensitive chemical shift for determining metal concentrations and/or measuring metal concentration changes, wherein the compound is selected from the group of: pyro-EGTA, EGTA, EDTA, AATA, APTRA, BAPTA, HIDA, citrate, CarboxyGlutamate (CGlu), arylazo chromotopic acid, beta-diketone (crown-ether), mono-, di-, or tri-pyridyl aniline, mono-, di-, or tri-pyridyl amine, trimethylphenylammonium, or derivatives thereof. The present invention further relates to biosensors comprising at least one of the compounds. The present invention also relates to the use of the compounds for diagnosing and/or monitoring treatment of a disease causing changes in metal concentrations. The present invention is furthermore related to in vitro and in vivo methods for determining metal concentration and/or measuring metal concentration changes using the compounds or biosensors. The present invention also relates to methods of diagnosing and/or monitoring treatment of a disease causing changes in metal concentrations wherein the compounds or biosensors are applied. The present invention also relates to use of the compounds or biosensors in quality control of food or in the examination of plants and organisms or for monitoring of environmental resources. The present invention further relates to novel derivatives of pyro-EGTA, AATA, APTRA and BAPTA as well as their uses.
摘要翻译：本发明涉及的化合物的用途与至少一种金属敏感性的化学位移为确定性采矿金属浓度和/或测量金属浓度的变化，worin所述化合物选自所组成的组：热释EGTA EGTA，EDTA，AATA， APTRA，BAPTA，HIDA，柠檬酸盐，羧基谷氨酸（cGlu），芳基偶氮chromotopic酸，β-二酮（冠醚），单 - ，二 - ，或三 - 吡啶基苯胺，单 - ，二 - ，或三 - 吡啶基胺，三甲基苯基，或它们的衍生物。本发明还涉及生物传感器包含所述化合物中的至少一种。因此，本发明涉及使用所述化合物的用于诊断和/或监测治疗疾病引起金属浓度的变化。本发明进一步更相关的体外和体内方法用于确定性采矿金属浓度和/或测量使用所述化合物或生物传感器的金属浓度的变化。因此，本发明涉及诊断和/或监测治疗疾病引起金属浓度的变化的方法worin化合物或生物传感器被应用。因此，本发明涉及在食品的质量控制或在植物和微生物的检查或用于环境资源的监测来使用这些化合物或生物传感器的。本发明还涉及热释EGTA，AATA，APTRA和BAPTA以及它们的用途的新的衍生物。

9. 发明公开

EP2958587A1 VACCINATION STRATEGY 审中-公开
标题翻译：疫苗策略
公开(公告)号：EP2958587A1
公开(公告)日：2015-12-30
申请号：EP14706057.8
申请日：2014-02-25
申请人： Klinikum rechts der Isar der Technischen Universität München , Technische Universität München , Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
发明人： KNOLLE, Percy , HEIKENWÄLDER, Mathias , PROTZER, Ulrike , HUANG, Li-Rung
IPC分类号： A61K39/39
CPC分类号： A61K39/292 , A61K39/39 , A61K2039/525 , C12N7/00 , C12N2730/10134 , C12N2730/10171
摘要： In a first aspect, the present invention relates to the use of a TLR 9 agonist and/or a TLR 4 agonist in a prophylactic or therapeutic vaccine. According to the present vaccination strategy, the TLR 9 agonist and/or TLR 4 agonist is adapted or designed for use as a multiplying jump agent to enhance numbers and functionality of CD8 T cells in a prime-jump vaccination strategy for jump T cell expansion. In particular, the TLR 9 agonist and/or TLR 4 agonist is used as a component to be administered after priming of the individual to be vaccinated. The vaccination strategy is particularly useful against acute and chronic infections with intracellular pathogens or for anti-tumor vaccination. In another aspect, the present invention relates to a kit of part containing a prime agent and a multiplying jump agent according to the present invention.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式